Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 118 clinical trials
None
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma

Multiple myeloma (MM) is the second most common hematologic malignancy in adults. The current standard of care for MM patients fit to undergo high dose conditioning chemotherapy is an autologous HCT (autoHCT). Allogeneic HCT (alloHCT) is the only potentially curative therapy available to patients with MM. However, the significant morbidity …

chemotherapy regimen
hematologic malignancy
plasma cell leukemia
cancer
cell transplantation
  • 108 views
  • 03 Feb, 2021
  • 1 location
None
Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice

There is a high unmet medical need for an anti-myeloma therapy for RRMM patients previously treated with Lenalidomide and Bortezomib, due to poor prognosis. This observational study

lenalidomide
maintenance therapy
refractory multiple myeloma
induction therapy
bortezomib
  • 38 views
  • 25 Jan, 2021
  • 13 locations
None
VMP Regimen - Safety Efficacy and Optimal Dose Finding Study for Patients With Multiple Myeloma

The 3-drug therapy of Bortezomib-Melphalan-Prednisolone (VMP) is a standard therapy that is commonly used currently in South Korea as a first-line treatment for treatment-nave patients with

bortezomib
melphalan
  • 1 views
  • 28 Jan, 2021
  • 22 locations
None
Secure Outsourcing of Carfilzomib in the Treatment of Multiple Myeloma to the Hospital at Home Setting

drugs administered by subcutaneous injection - in particular, bortezomib and azacytidine - are applicable to carfilzomib following minor modifications to the procedures given the IV administration of

multiple myeloma
cancer
  • 0 views
  • 17 Oct, 2021
  • 1 location
None
Use Lenalidomide (Revlimid ) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients

The aim of this non-interventional study is to collect primarily the percentage of patients who receive the full dose of dexamethasone (20 or 40 mg orally once daily on days 1, 8, 15 and 22 of the repetitive 28-day cycles, 20 mg in >75 year old patients) in the registered …

lenalidomide
cell transplantation
dexamethasone
revlimid
  • 38 views
  • 26 Jan, 2021
  • 12 locations
None
Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With Multiple Myeloma

The study aims to compare the overall survival adjusted to quality of life of 2 groups of patients with multiple myeloma, depending on the type of care: (1) day hospitalization exclusively or (2) day hospitalization combined with hospital-at-home. As secondary objectives, the study aims to compare the impacts of the …

cyclophosphamide
melphalan
bortezomib
velcade
dexamethasone
  • 0 views
  • 14 Apr, 2021
  • 1 location
None
Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma

A total of 40 Multiple Myeloma (MM) patients at clinical relapse who progressed during Proteasome Inhibitors (PIs) or Immunomodulating Drugs (IMiDs)-based therapies and who are assigned to antiCD38-based salvage treatments, will be enrolled. We will collect bone marrow (BM) and peripheral blood (PB) samples from patients at specific timepoints: baseline …

  • 0 views
  • 07 May, 2021
  • 1 location
None
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression

Based on our previous observations, here the investigator plans to further investigate eNAMPT in MM biology and to establish its role in disease progression where EMT acquisition represents an hallmark of cancers. Results deriving from proposal would hopefully identify novel biological vulnerabilities of such malignancy and an innovative biomarker for …

bone marrow procedure
  • 0 views
  • 29 Aug, 2021
  • 1 location